Skip to main content
PALISADE BIO, INC. logo

PALISADE BIO, INC. — Investor Relations & Filings

Ticker · PALI ISIN · US6963894026 LEI · 549300W6LIDX3I5XXT34 US Manufacturing
Filings indexed 1,045 across all filing types
Latest filing 2025-11-12 Regulatory Filings
Country US United States of America
Listing US PALI

About PALISADE BIO, INC.

https://palisadebio.com/

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company that develops and advances novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases. The company focuses on next-generation precision therapies, utilizing its phosphodiesterase-4 (PDE4) inhibitor prodrug platform. This platform is engineered to enable the targeted, oral delivery of therapeutics specifically to the gastrointestinal tract, aiming to enhance efficacy at the disease site while minimizing systemic side effects. Its lead development candidate, PALI-2108, is an oral PDE4 inhibitor prodrug being investigated for the treatment of inflammatory bowel diseases like ulcerative colitis.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings
2025-11-12 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-10 English
Director's Dealing 2025
Director's Dealing
2025-11-06 English
4/A
Director's Dealing
2025-11-06 English
4/A
Director's Dealing
2025-11-06 English
DEFA14A
Regulatory Filings
2025-11-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.